NanoLogix Rapid Diagnostic Technologies Set to Enter Market Under FDA 510K-Exempt Status
00:51 EDT 21 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
NanoLogix
(Pink Sheets: NNLX), a biotechnology innovator in the rapid detection
and identification of live-threat bacteria and microorganisms, announces
it will begin commercialization of its BNP (BioNanoPore) and BNF
(Bi...
Other Sources for this Article
Media Contact:
Technica
Communications
Lisa Ann Pinkerton, 408-806-9626
Lisaann@technicacommunications.com
or
Investor
Contact:
NanoLogix, Inc.
Carol Surrena, 330-534-0800
carol@nanologix.com
More From BioPortfolio on "NanoLogix Rapid Diagnostic Technologies Set to Enter Market Under FDA 510K-Exempt Status"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
